Epie Boven

Pertuzumab Plus Trastuzumab with or Without Chemotherapy Followed by Emtansine in ERBB2 -Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Huober, J., Weder, P., Ribi, K., Thürlimann, B., Thery, J-C., Li, Q., Vanlemmens, L., Guiu, S. V., Brain, E., Grenier, J., Dalenc, F., Levy, C., Savoye, A-M., Müller, A., Membrez-Antonioli, V. R., Gérard, M-A., Lemonnier, J. R., Hawle, H., Dietrich, D., Boven, E., & 1 othersBonnefoi, H., 19 Oct 2023, In: JAMA Oncology. 9, 10, p. 1381-1389 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer

Bos, M. K., Lam, S. W., Motta, G., Helmijr, J. C. A., Beaufort, C. M., de Jonge, E., Martens, J. W. M., Boven, E., Jansen, M. P. H. M., Jager, A. & Sleijfer, S., Jul 2023, In: Breast cancer research and treatment. 200, 2, p. 271-279 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

Bhin, J., Yemelyanenko, J., Chao, X., Klarenbeek, S., Opdam, M., Malka, Y., Hoekman, L., Kruger, D., Bleijerveld, O., Brambillasca, C. S., Sprengers, J., Siteur, B., Annunziato, S., van Haren, M. J., Martin, N. I., van de Ven, M., Peters, D., Agami, R., Linn, S. C., Boven, E., & 4 othersAltelaar, M., Jonkers, J., Zingg, D. & Wessels, L. F. A., 2023, In: Journal of Experimental Medicine. 220, 11, e20211743.

Research output: Contribution to journal › Article › Academic › peer-review